Senexis Limited And BioFocus Collaborate To Select Development Candidates For Senexis' Alzheimer's Disease Targets

Senexis Limited, a private drug development company, and Galapagos NV (Euronext & LSE: GLPG), a genomics based drug discovery company, announced today that they have expanded their collaboration to optimise Senexis' novel inhibitors of amyloid-induced toxicity and neuroinflammation for the treatment of Alzheimer's disease. Galapagos will receive research fees for the medicinal chemistry services provided to Senexis. The collaboration aims to significantly advance Senexis' small molecule Alzheimer's programs towards the clinic and is unrelated to Galapagos' own Alzheimer's disease targets program.